Stock PERP B PHARMACOLOG I UPPSALA AB
Add to a list
To use this feature you must be a member
Log inSign up

All News Pharmacolog i Uppsala AB

Equities

PERP B

SE0019071812

Market Closed - Nasdaq Stockholm
Other stock markets
 09:30:00 28/06/2024 pm IST 		5-day change 1st Jan Change
0.133 SEK -0.75% Intraday chart for Pharmacolog i Uppsala AB +23.15% +134.98%
18/06 Perpetua Medical AB (OM:PERP B) signed a letter of intent to acquire 70% stake in Es-Medical Ab for SEK 5.2 million. CI
12/06 Nolsterby Invest AB Offers A Loan Facility of Up to SEK 25 Million to Perpetua Medical AB CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Perpetua Medical AB (OM:PERP B) signed a letter of intent to acquire 70% stake in Es-Medical Ab for SEK 5.2 million.
CI
Nolsterby Invest AB Offers A Loan Facility of Up to SEK 25 Million to Perpetua Medical AB
CI
Perpetua Medical publishes interim report January - March 2024
AQ
Perpetua Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Perpetua Medical AB (formerly Pharmacolog i Uppsala AB) appoints Camilla Lönn as CFO
AQ
Perpetua Medical AB Appoints Camilla Lonn as CFO
CI
Perpetua Medical AB (formerly Pharmacolog i Uppsala AB) announces its first day of trading on Nasdaq First North under its new company name
AQ
Pharmacolog i Uppsala AB will Change its Ticker to PERP B from PHLOG B
CI
Pharmacolog i Uppsala AB will Change its Name to Perpetua Medical AB
CI
ANNOUNCEMENT FROM THE EXTRAORDINARY GENERAL MEETING OF PHARMACOLOG I UPPSALA AB ON APRIL 16, 2024
AQ
Pharmacolog publishes annual report for 2023
AQ
Nolsterby Invest AB has increased its holding in Pharmacolog
AQ
Pharmacolog announces the appointment of Anders Hedlund as interim CEO
AQ
Pharmacolog i Uppsala AB Announces the Appointment of Anders Hedlund as Interim CEO, Effective from May 1, 2024
CI
NOTICE TO EXTRAORDINARY GENERAL MEETING IN PHARMACOLOG I UPPSALA AB (PUBL)
AQ
Pharmacolog provides update on new business direction and proposes name change
AQ
Pharmacolog announces upcoming change in management
AQ
Pharmacolog Announces Resignation of Lars Gusch as CEO, Effective from April 30, 2024
CI
Warrants of series TO3 were subscribed to approximately 90.4 percent and Pharmacolog receives approximately SEK 2.3 million
AQ
Major shareholder in Pharmacolog exercises warrants of series TO3 for at least approximately SEK 0.54 million
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PERP B Stock
  4. News Pharmacolog i Uppsala AB